+12.1%
HLT vs MRNA
+511.3%
-499.2%
-11.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.0% | -2.2% | +1.2% | -1.0% |
| 7D | -3.3% | +5.5% | -8.8% | -3.4% |
| 30D | -4.1% | +158.7% | -162.8% | -7.4% |
| 3M | -7.9% | +182.1% | -190.1% | -11.6% |
| 6M | +2.2% | +151.8% | -149.7% | -1.7% |
| YTD | +8.5% | +393.6% | -385.1% | +0.2% |
| 1Y | +12.1% | +499.5% | -487.3% | +1.7% |
| All | +12.1% | +511.3% | -499.2% | +1.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling